Last reviewed · How we verify
Stemchymal®
At a glance
| Generic name | Stemchymal® |
|---|---|
| Sponsor | Steminent Biotherapeutics Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Stemchymal® for Polyglutamine Spinocerebellar Ataxia (PHASE2)
- Safety Study of Stemchymal® in Acute Liver Failure (PHASE1)
- Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stemchymal® CI brief — competitive landscape report
- Stemchymal® updates RSS · CI watch RSS
- Steminent Biotherapeutics Inc. portfolio CI